QuestionAugust 17, 2025

Which statement about ezetimibe is INCORRECT? It results in a reactive increase in LDL receptors. It inhibits the absorption of cholesterol from the small intestine. It is a prodrug that requires glucuronidation to exert its biological effect. Expect a 20% reduction in cholesterol when used as monotherapy. There is no increase in the risk for hepatoxicity when combined with statins.

Which statement about ezetimibe is INCORRECT? It results in a reactive increase in LDL receptors. It inhibits the absorption of cholesterol from the small intestine. It is a prodrug that requires glucuronidation to exert its biological effect. Expect a 20% reduction in cholesterol when used as monotherapy. There is no increase in the risk for hepatoxicity when combined with statins.
Which statement about ezetimibe is INCORRECT? It results in a reactive increase in LDL receptors. It inhibits the absorption of cholesterol from the small intestine. It is a prodrug that requires glucuronidation to exert its biological effect. Expect a 20% reduction in cholesterol when used as monotherapy. There is no increase in the risk for hepatoxicity when combined with statins.

Solution
4.6(258 votes)

Answer

It is a prodrug that requires glucuronidation to exert its biological effect. Explanation 1. Identify the incorrect statement Analyze each statement about ezetimibe: - **Reactive increase in LDL receptors**: Correct, as ezetimibe lowers cholesterol absorption, leading to increased LDL receptor activity. - **Inhibits absorption of cholesterol from the small intestine**: Correct, this is the primary mechanism of action for ezetimibe. - **Prodrug requiring glucuronidation**: Incorrect, ezetimibe itself is active and does not require conversion to exert its effect. - **20\% reduction in cholesterol as monotherapy**: Correct, ezetimibe typically reduces cholesterol by approximately 18\%-25\%. - **No increase in risk for hepatotoxicity with statins**: Correct, ezetimibe does not significantly increase hepatotoxicity risk when combined with statins.

Explanation

1. Identify the incorrect statement<br /> Analyze each statement about ezetimibe:<br />- **Reactive increase in LDL receptors**: Correct, as ezetimibe lowers cholesterol absorption, leading to increased LDL receptor activity.<br />- **Inhibits absorption of cholesterol from the small intestine**: Correct, this is the primary mechanism of action for ezetimibe.<br />- **Prodrug requiring glucuronidation**: Incorrect, ezetimibe itself is active and does not require conversion to exert its effect.<br />- **$20\%$ reduction in cholesterol as monotherapy**: Correct, ezetimibe typically reduces cholesterol by approximately $18\%-25\%$.<br />- **No increase in risk for hepatotoxicity with statins**: Correct, ezetimibe does not significantly increase hepatotoxicity risk when combined with statins.
Click to rate:

Similar Questions